The value and pricing outputs from the DELPHI panel, and accompanying advisory board were key elements informing the internal decision-making framework surrounding the Phase 3b multiple comparator study.
Inbeeos’ client wishes to understand payers’ perspectives on the added value of performing a Phase 3b multiple comparator study of their asset in drug-resistant epilepsy (DRE).
The DRE landscape is highly competitive, and it is critical to understand factors which can differentiate a new drug from its competitors. An active-comparator trial requires significant investment and carries potential risks, and so the potential added value from a 3b study must be compelling.
HOW WE APPROACHED THE CHALLENGE
We used an adapted DELPHI approach, which enabled the establishment of consensus through agreement or disagreement to a series of carefully selected statements, over two rounds of survey. Key study outcome scenarios were tested in terms of their likely impact on reimbursement, pricing and tier placement.
The results of the DELPHI survey were combined with qualitative insights generated through an advisory board held with US payers. This allowed for a deep and unbiased understanding of payers’ preferences on multiple aspects of the potential Phase 3b study.